Legislative

New Legislation Aims to Prohibit DIR FeesBills have been introduced in both the Senate and House that are aimed at stopping direct and indirect remuneration fees, assuming they are passed.
New bill aims to support generic, biosimilar drug competitionThe CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development.
Pharmacy education and provider statusA 60-year debate accompanied the elevation of pharmacy education to the doctoral level. When the provider status bill now moving through Congress is enacted into law, it will put paid to that particular conversation.
NCPA Congressional Pharmacy Summit advocates for clarity around Rx drug pricingMore than 300 pharmacists turned out to support H.R. 244, the “MAC Transparency Act," and H.R. 793, the “Ensuring Seniors Access to Local Pharmacies Act of 2015.”
Provider statusWith provider status now a reality in 38 states, HR 592 and S 314 have powerful Congressional support. How long before the payers come on board?
Arizona passes pharmacy biosimilar lawArizona recently joined around 20 other states by passing a law allowing pharmacists to substitute certain interchangeable biosimilar drugs for brand name drugs.
Pharmacists seek fairness in generics reimbursementPBMs have dodged state-mandated requirements for transparency in generics drug pricing, so many states are rewriting their laws.
Below-cost Rxs: One state just says noStarting in July, a new law in Mississippi will allow a pharmacy to refuse to provide drugs or services if it is not paid more than acquisition cost.
Pharmacy choice bill diesIndependent pharmacists in Colorado are disappointed after a Senate committee killed the “Pharmacy Choice Act” before it could come up for a vote.
NACDS, NCPA support passage of drug-abuse billThe law aims to reduce prescription drug abuse while ensuring access for patients who need Rx painkillers to control their chronic pain.